Literature DB >> 16375742

Lifelong endocrine fluctuations and related cognitive disorders.

M L Ancelin1, K Ritchie.   

Abstract

The aim of this review is to examine the relationship between endocrine fluctuation and cognitive functioning. A plethora of in vitro and in vivo studies has demonstrated the neuroprotective role of estrogens and their impact on the neurotransmitter systems implicated in cognition. Recent hormonal replacement therapy (HRT) trials in non-demented post-menopausal women suggest a temporary positive effect (notably on verbal memory), and four recent meta-analyses converge to suggest a possible protective effect in relation to Alzheimer's disease (reducing risk by 29 to 44%). However, data from the only large randomised controlled trial published to date, the Women's Health Initiative Memory Study, did not confirm these observations and have even suggested an increase in dementia risk for women using HRT compared to controls. Several methodological differences between observation studies and controlled trials with regard to patient group, type, timing and duration of HRT, cognitive measures and analyses, are discussed to explain these discrepancies. The association between hormonal serum level and cognitive functioning remains controversial suggesting high inter-individual vulnerability in risk. Moreover, research on the impact of endocrine functioning on cognition during the female reproductive cycle suggests life-long fluctuations in vulnerability. Etiological models taking into account the interaction of clinical, reproductive, and menstrual events throughout life may provide a more valid approach in understanding the effects of steroids on the brain and in determining sub-groups at heightened risk. Cognitive disorders in the elderly are more likely be related to cumulated lifelong exposure to steroids, rather than to a specific exposure to a given steroid. Multifactorial models based on an exhaustive view of all hormonal events throughout reproductive life together with other risk factors (notably genetic risk factors related to estrogen receptor polymorphisms) should be explored to clarify the role of hormonal risk factors, or protective factors for cognitive dysfunction and dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375742     DOI: 10.2174/138161205774913228

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  21 in total

1.  Effects of synaptic plasticity regulated by 17beta-estradiol on learning and memory in rats with Alzheimer's disease.

Authors:  Xiu-Li Shang; Jiu-Han Zhao; Yun-Peng Cao; Yi-Xue Xue
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

2.  Differential effects on visual and spatial recognition memory of a novel hormone therapy regimen of estrogen alone or combined with progesterone in older surgically menopausal monkeys.

Authors:  M L Voytko; C J Higgs; R Murray
Journal:  Neuroscience       Date:  2008-05-03       Impact factor: 3.590

3.  A prospective study of hormone therapy and depression in community-dwelling elderly women: the Three City Study.

Authors:  Jacqueline Scali; Joanne Ryan; Isabelle Carrière; Jean-François Dartigues; Béatrice Tavernier; Karen Ritchie; Marie-Laure Ancelin
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

Review 4.  Interactive effects of age and estrogen on cortical neurons: implications for cognitive aging.

Authors:  M E Bailey; A C J Wang; J Hao; W G M Janssen; Y Hara; D Dumitriu; P R Hof; J H Morrison
Journal:  Neuroscience       Date:  2011-06-02       Impact factor: 3.590

5.  Sex differences in the associations between lipid levels and incident dementia.

Authors:  Marie-Laure Ancelin; Emmanuelle Ripoche; Anne-Marie Dupuy; Pascale Barberger-Gateau; Sophie Auriacombe; Olivier Rouaud; Claudine Berr; Isabelle Carrière; Karen Ritchie
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors.

Authors:  K Ritchie; I Carrière; C W Ritchie; C Berr; S Artero; M-L Ancelin
Journal:  BMJ       Date:  2010-08-05

7.  Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study.

Authors:  J Ryan; I Carrière; J Scali; J F Dartigues; C Tzourio; M Poncet; K Ritchie; M L Ancelin
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

Review 8.  Hormonal treatment, mild cognitive impairment and Alzheimer's disease.

Authors:  Joanne Ryan; Jaqueline Scali; Isabelle Carriere; Karen Ritchie; Marie-Laure Ancelin
Journal:  Int Psychogeriatr       Date:  2008-02       Impact factor: 3.878

9.  Effects of two years of conjugated equine estrogens on cholinergic neurons in young and middle-aged ovariectomized monkeys.

Authors:  Carole Browne; Joseph R Tobin; Mary Lou Voytko
Journal:  Brain Res       Date:  2009-01-20       Impact factor: 3.252

10.  Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.

Authors:  Isabelle Carrière; Annie Fourrier-Reglat; Jean-François Dartigues; Olivier Rouaud; Florence Pasquier; Karen Ritchie; Marie-Laure Ancelin
Journal:  Arch Intern Med       Date:  2009-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.